The FDA has approved an updated label for UNLOXCYT (cosibelimab-ipdl) based on promising long-term data showing durable responses in advanced cutaneous squamous cell carcinoma (aCSCC). The trial demonstrated that over 50% of patients achieved objective responses, with median duration of response not reached. Sun Pharma plans to launch UNLOXCYT commercially in early 2026, reinforcing its role as an innovative immunotherapy option for aCSCC patients.